Alzheimer's Disease Retromer and Endosomal Trafficking Companies
📖 Wiki Page
company743 wordssynced 2026-04-02
Overview
This category covers biotechnology and pharmaceutical companies developing therapeutics that target retromer dysfunction and endosomal trafficking impairments in Alzheimer's disease. The retromer complex — comprising VPS35, VPS26, and VPS29 — is a critical regulator of protein trafficking between endosomes and the Golgi apparatus or plasma membrane. Genetic studies have identified the VPS35 p.D620N mutation as a risk factor for familial Parkinson's disease, and retromer dysfunction is increasingly recognized as a contributor to amyloid-beta and tau pathology in AD[@mcgough2017].
Endosomal trafficking deficits are among the earliest cellular abnormalities in Alzheimer's disease, preceding clinical symptoms by decades. Impaired retrograde transport from endosomes to the Golgi disrupts amyloid precursor protein (APP) processing, leading to increased amyloid-beta production. Additionally, endosomal dysfunction contributes to tau propagation through extracellular vesicle-mediated spread.
Key Companies
Alterity Therapeutics (VPS35 Modulators)
...
Overview
This category covers biotechnology and pharmaceutical companies developing therapeutics that target retromer dysfunction and endosomal trafficking impairments in Alzheimer's disease. The retromer complex — comprising VPS35, VPS26, and VPS29 — is a critical regulator of protein trafficking between endosomes and the Golgi apparatus or plasma membrane. Genetic studies have identified the VPS35 p.D620N mutation as a risk factor for familial Parkinson's disease, and retromer dysfunction is increasingly recognized as a contributor to amyloid-beta and tau pathology in AD[@mcgough2017].
Endosomal trafficking deficits are among the earliest cellular abnormalities in Alzheimer's disease, preceding clinical symptoms by decades. Impaired retrograde transport from endosomes to the Golgi disrupts amyloid precursor protein (APP) processing, leading to increased amyloid-beta production. Additionally, endosomal dysfunction contributes to tau propagation through extracellular vesicle-mediated spread.
Mechanism: Modulates retromer complex function to restore proper endosomal trafficking
Science: Alterity's platform targets the retromer cargo recognition complex, enhancing the trafficking of proteins involved in APP processing and reducing amyloidogenic cleavage products